GlaxoSmithKline ( (GSK)) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors. GlaxoSmithKline (GSK) is a global biopharmaceutical ...

known also by its non-commercial name ranitidine, was manufactured by several rivals including the French group Sanofi and US drugmaker Pfizer before it was withdrawn in 2019. In recent years GSK ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning, it’s a busy ...

The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim. Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could ...

Vaccine manufacturer GSK plans to invest $800 million in its County facility, creating 200 new jobs and expanding its ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.